ClinicalTrials.gg
CompletedNCT01292837Updated May 15, 2015Results posted

A Study of Levetiracetam in Japanese Pediatric Patients With Generalized Tonic-clonic Seizures

A Phase 3 interventional study of Levetiracetam in Epilepsy and Generalized Tonic-clonic Seizures, sponsored by UCB Japan Co. Ltd.. Completed at 26 sites in Japan. Open to participants aged 4 Years to 15 Years. Per ClinicalTrials.gov, last updated 2015-05-15.

Sponsored by UCB Japan Co. Ltd. (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
4 Years to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.

Enrollment
53rd of 60
13 · median 94
Started
2011
with 4 others
Phase 3
28 of 60
2 open now
Registered
39th of 60
by date
Lead sponsor
7 of 60
UCB Japan Co. Ltd.

Among the 60 studies testing levetiracetam in Epilepsy, this one is the 53rd largest by enrollment, is one of 5 that started in 2011, is one of 28 in phase 3, and was the 39th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 4 Years to 15 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing levetiracetam in Epilepsy, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of Levetiracetam dry syrup at doses up to 60 mg/kg/day or 3000 mg/day used as adjunctive therapy in Japanese pediatric patients aged ≥4 to \<16 years with uncontrolled Generalized Tonic-Clonic (GTC) seizures despite treatment with 1 or 2 Anti-Epileptic Drugs (AEDs).

03

Conditions studied

  • Epilepsy
  • Generalized Tonic-clonic Seizures

Keywords

  • Levetiracetam
  • Epilepsy
  • Generalized tonic-clonic seizures
04

Who can participate

Ages eligible
4 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An epileptic patient with generalized tonic-clonic seizures that are classifiable according to the International League Against Epilepsy classification of epileptic seizures (Epilepsia, 1981)
  • A patient on a stable dose of 1 or 2 anti-epileptic drugs for the last 4 weeks (potassium bromide and sodium bromide for the last 12 weeks) prior to the Combined Baseline Period and during the Combined Baseline Period

Exclusion criteria

Exclusion Criteria:

  • Presence of any sign (clinical or imaging procedures) suggesting a progressive brain lesion/disease, in particular, progressive disorder with epileptic seizures
  • Diagnosis of Lennox-Gastaut Syndrome
  • Confirmed focal epilepsy based on clinical signs (seizure types), with consistent electroencephalogram and magnetic resonance imaging features
  • A history of convulsive or nonconvulsive status epilepticus while taking concomitant anti-epileptic drugs for the last 3 months prior to Visit 1
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Levetiracetam

    Twice daily (morning and evening) orally

    Drug: Levetiracetam

Interventions

  • The initial dose is 20 mg/kg/day or 1000 mg/day, divided into two equal dose for the first two weeks, followed by 40 mg/kg/day or 2000 mg/day for two weeks. After reaching 60 mg/kg/day or 3000 mg/day, treatment will continue for 20 weeks.

    Also known as: Keppra, E Keppra

06

What researchers measure

Primary outcomes

  1. The Percent Change From the Combined Baseline (4-week Retrospective Baseline and 4-week Prospective Baseline) in the Generalized Tonic-clonic Seizure Frequency Per Week Over the 24-week Treatment Period (Up-Titration and Evaluation Periods)

    The percent change from Combined Baseline over Treatment Period was calculated from the Generalized Tonic-Clonic (GTC) seizure frequency per week during the Treatment Period (T) and during the Baseline Period (B, Combined Baseline, ie, Retrospective and Prospective Baseline Periods) using the equation below. The percent change from Baseline = (B - T)/B x 100 The seizure frequency per week was calculated using the following formula: Frequency per week of GTC seizures = total number of GTC seizures in the corresponding period / number of days for observation in the corresponding period x 7

    Time frame: From Baseline (Week -8) to Treatment Period (Week 0 to Week 24)

Secondary outcomes

  1. The Percent Change in Generalized Tonic-clonic Seizure Frequency Per Week From the Combined Baseline Period Over the Evaluation Period

    The percent change from Combined Baseline over Evaluation Period was calculated from the Generalized Tonic-Clonic (GTC) seizure frequency per week during the Evaluation Period (E) and during the Baseline Period (B, Combined Baseline, ie, Retrospective and Prospective Baseline Periods) using the equation below. The percent change from Baseline = (B - E)/B x 100 The seizure frequency per week was calculated using the following formula: Frequency per week of GTC seizures = total number of GTC seizures in the corresponding period / number of days for observation in the corresponding period x 7

    Time frame: From Baseline (Week -8) to Evaluation Period (Week 4 to Week 24)

  2. Generalized Tonic-clonic Seizures 50 % Responder Rate (the Proportion of Subjects With 50 % or More Reduction From the Combined Baseline in the Frequency of Generalized Tonic-clonic Seizures) During the Treatment Period

    The 50 % responder rate during the Treatment Period was the proportion of subjects who reported a ≥ 50 % reduction in seizure frequency per week from Baseline during the Treatment Period.

    Time frame: From Baseline (Week -8) to Treatment Period (Week 0 to Week 24)

  3. Generalized Tonic-clonic Seizures 50 % Responder Rate During the Evaluation Period

    The 50 % responder rate during the Evaluation Period was the proportion of subjects who reported a ≥50 % reduction in seizure frequency per week from Baseline during the Evaluation Period.

    Time frame: From Baseline (Week -8) to Evaluation Period (Week 4 to Week 24)

  4. Generalized Tonic-clonic Seizure Freedom Over the Treatment Period

    A subject with a generalized tonic-clonic seizure frequency of 0 per week throughout the Treatment Period was considered a seizure-free subject for that period.

    Time frame: Treatment Period (Week 0 to Week 24)

  5. Generalized Tonic-clonic Seizure Freedom Over the Evaluation Period

    A subject with a generalized tonic-clonic seizure frequency of 0 per week throughout the Evaluation Period was considered a seizure-free subject for that period.

    Time frame: Evaluation Period (Week 4 to Week 24)

07

Results

Posted Aug 12, 2014

Participant flow

This multicenter study started to enroll subjects in Februray 2011 in order to end up with 8 sites in Japan with enrolled subjects. Participant Flow refers to the Enrolled Set (ES). ES consists of all subjects who signed the consent form and participated in the Prospective Baseline Period.

Participant flow — Overall Study
MilestoneLevetiracetam
Started13
Completed11
Not completed2
Withdrew: Adverse event1
Withdrew: Further treatment determined1

Outcome measures

PrimaryThe Percent Change From the Combined Baseline (4-week Retrospective Baseline and 4-week Prospective Baseline) in the Generalized Tonic-clonic Seizure Frequency Per Week Over the 24-week Treatment Period (Up-Titration and Evaluation Periods)

The percent change from Combined Baseline over Treatment Period was calculated from the Generalized Tonic-Clonic (GTC) seizure frequency per week during the Treatment Period (T) and during the Baseline Period (B, Combined Baseline, ie, Retrospective and Prospective Baseline Periods) using the equation below. The percent change from Baseline = (B - T)/B x 100 The seizure frequency per week was calculated using the following formula: Frequency per week of GTC seizures = total number of GTC seizures in the corresponding period / number of days for observation in the corresponding period x 7

Time frame:
From Baseline (Week -8) to Treatment Period (Week 0 to Week 24)
Reported as:
Mean · percent change
The Percent Change From the Combined Baseline (4-week Retrospective Baseline and 4-week Prospective Baseline) in the Generalized Tonic-clonic Seizure Frequency Per Week Over the 24-week Treatment Period (Up-Titration and Evaluation Periods)
percent changeLevetiracetam
The Percent Change From the Combined Baseline (4-week Retrospective Baseline and 4-week Prospective Baseline) in the Generalized Tonic-clonic Seizure Frequency Per Week Over the 24-week Treatment Period (Up-Titration and Evaluation Periods)45.47 ± 50.34
SecondaryThe Percent Change in Generalized Tonic-clonic Seizure Frequency Per Week From the Combined Baseline Period Over the Evaluation Period

The percent change from Combined Baseline over Evaluation Period was calculated from the Generalized Tonic-Clonic (GTC) seizure frequency per week during the Evaluation Period (E) and during the Baseline Period (B, Combined Baseline, ie, Retrospective and Prospective Baseline Periods) using the equation below. The percent change from Baseline = (B - E)/B x 100 The seizure frequency per week was calculated using the following formula: Frequency per week of GTC seizures = total number of GTC seizures in the corresponding period / number of days for observation in the corresponding period x 7

Time frame:
From Baseline (Week -8) to Evaluation Period (Week 4 to Week 24)
Reported as:
Mean · percent change
The Percent Change in Generalized Tonic-clonic Seizure Frequency Per Week From the Combined Baseline Period Over the Evaluation Period
percent changeLevetiracetam
The Percent Change in Generalized Tonic-clonic Seizure Frequency Per Week From the Combined Baseline Period Over the Evaluation Period44.93 ± 51.86
SecondaryGeneralized Tonic-clonic Seizures 50 % Responder Rate (the Proportion of Subjects With 50 % or More Reduction From the Combined Baseline in the Frequency of Generalized Tonic-clonic Seizures) During the Treatment Period

The 50 % responder rate during the Treatment Period was the proportion of subjects who reported a ≥ 50 % reduction in seizure frequency per week from Baseline during the Treatment Period.

Time frame:
From Baseline (Week -8) to Treatment Period (Week 0 to Week 24)
Reported as:
Number · percentage of participants
Generalized Tonic-clonic Seizures 50 % Responder Rate (the Proportion of Subjects With 50 % or More Reduction From the Combined Baseline in the Frequency of Generalized Tonic-clonic Seizures) During the Treatment Period
percentage of participantsLevetiracetam
Generalized Tonic-clonic Seizures 50 % Responder Rate (the Proportion of Subjects With 50 % or More Reduction From the Combined Baseline in the Frequency of Generalized Tonic-clonic Seizures) During the Treatment Period53.8
SecondaryGeneralized Tonic-clonic Seizures 50 % Responder Rate During the Evaluation Period

The 50 % responder rate during the Evaluation Period was the proportion of subjects who reported a ≥50 % reduction in seizure frequency per week from Baseline during the Evaluation Period.

Time frame:
From Baseline (Week -8) to Evaluation Period (Week 4 to Week 24)
Reported as:
Number · percentage of participants
Generalized Tonic-clonic Seizures 50 % Responder Rate During the Evaluation Period
percentage of participantsLevetiracetam
Generalized Tonic-clonic Seizures 50 % Responder Rate During the Evaluation Period58.3
SecondaryGeneralized Tonic-clonic Seizure Freedom Over the Treatment Period

A subject with a generalized tonic-clonic seizure frequency of 0 per week throughout the Treatment Period was considered a seizure-free subject for that period.

Time frame:
Treatment Period (Week 0 to Week 24)
Reported as:
Number · participants
Generalized Tonic-clonic Seizure Freedom Over the Treatment Period
participantsLevetiracetam
Generalized Tonic-clonic Seizure Freedom Over the Treatment Period2
SecondaryGeneralized Tonic-clonic Seizure Freedom Over the Evaluation Period

A subject with a generalized tonic-clonic seizure frequency of 0 per week throughout the Evaluation Period was considered a seizure-free subject for that period.

Time frame:
Evaluation Period (Week 4 to Week 24)
Reported as:
Number · participants
Generalized Tonic-clonic Seizure Freedom Over the Evaluation Period
participantsLevetiracetam
Generalized Tonic-clonic Seizure Freedom Over the Evaluation Period2

Adverse events

Collected over Treatment Emergent Adverse Events were reported from Baseline up to Week 30. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levetiracetam—0/13 (0%)13/13 (100%)
Most frequent other events
Showing 10 of 25
Most frequent other events
EventLevetiracetam
NasopharyngitisInfections and infestations3/13
ConvulsionNervous system disorders3/13
SomnolenceNervous system disorders3/13
DiarrhoeaGastrointestinal disorders2/13
Dental cariesGastrointestinal disorders1/13
StomatitisGastrointestinal disorders1/13
PyrexiaGeneral disorders1/13
ImpetigoInfections and infestations1/13
Otitis mediaInfections and infestations1/13
Pneumonia mycoplasmalInfections and infestations1/13

Baseline characteristics

The Baseline Analysis Population refers to the Safety Set. The Safety Set was a subset of the Enrolled Set and consisted of all subjects taking at least 1 dose of the study medication.

Age, Continuous
Age, Continuous(years)Levetiracetam
Mean9.7 ± 4.1
Age, Customized
Age, Customized(participants)Levetiracetam
≥4 to <8 years4
≥8 to <12 years2
≥12 to <16 years7
Sex: Female, Male
Sex: Female, Male(Participants)Levetiracetam
Female4
Male9
Region of Enrollment
Region of Enrollment(participants)Levetiracetam
Japan13
Weight
Weight(kilogram)Levetiracetam
Mean32.22 ± 16.56
Height
Height(centimeter)Levetiracetam
Mean129.36 ± 26.32
Body Mass Index
Body Mass Index(kilogram per squaremeter (kg/m^2))Levetiracetam
Mean17.89 ± 3.75
08

Study locations

26 sites
  • 191
    Akita, Japan
  • 184
    Bunkyo, Japan
  • 309
    Bunkyo, Japan
  • 107
    Gifu, Japan
  • 303
    Hiroshima, Japan
  • 108
    Kobe, Japan
  • 302
    Kodaira, Japan
  • 306
    Koshi, Japan
  • 136
    Moriyama, Japan
  • 305
    Nagoya, Japan
  • 190
    Nerima, Japan
  • 125
    Neyagawa, Japan
  • 301
    Niigata, Japan
  • 116
    Ohmura, Japan
  • 109
    Okayama, Japan
  • 308
    Onojo, Japan
  • 119
    Saitama, Japan
  • 117
    Sapporo, Japan
  • 304
    Sapporo, Japan
  • 103
    Sendai, Japan
  • 138
    Shimotsuke, Japan
  • 307
    Shizuoka, Japan
  • 139
    Takatsuki, Japan
  • 135
    Tsu, Japan
  • 193
    Yokohama, Japan
  • 310
    Yufu, Japan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2011
First posted
Feb 10, 2011
Start
Feb 2011
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Results first posted
Aug 12, 2014
Last update
May 15, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01292837
Lead sponsor
UCB Japan Co. Ltd.
Responsible party
Sponsor
First posted
Feb 10, 2011
Start date
Feb 2011
Primary completion
Jun 2013
Completion
Jun 2013
Results posted
Aug 12, 2014
Last update
May 15, 2015

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion